Anbiping
Huangpu · Founded 2005
About Anbiping
Anbiping is a number of reagents and supporting devices have indeed been independently created by Anbiping, which focuses on tumour screening and correct diagnosis. Pathology is the main application department. It has been established that product lines for liquid-based cytology, polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization can be used to screen for and diagnose tumors based on everything from cell morphology to protein expression.
Company Facts
- Founded: 2005
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $50K – $100K
- Total funding: $9.8M
- Funding stage: M&A
- Last round: Series C (Jun 2017)
- Ticker: sse:688393
- Website: http://www.gzlbp.com/
- Phone: +86-020-32299997
Industries & Categories
Biopharma, Biotechnology, Health Care, Health Diagnostics, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/anbiping-208303 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.